Award candidates and winners to be presented on October 26, 2023, at the Prix Galien USA Forum in NYC.
The Galien Foundation announced the 2023 Prix Galien USA Award nominees for "Best Digital Health Solution," "Best Medical Technology," and "Incubators, Accelerators and Equity." And, in partnership with Business France, nominees have also been announced for "Best Startup." Winners will be announced during the Prix Galien USA Forum on October 26, 2023, at the Alexandria Center for Life Science in New York City. Nominees in the "Best Medical Technology" category will be previewed during the Prix Galien USA Forum and, later that evening, category winners will be announced during the Prix Galien USA Awards Ceremony at the American Museum of Natural History in New York City.
"The Prix Galien Awards Committee is delighted to celebrate this remarkable group of candidates and selecting this year's winners will be no easy feat," said Bernard Poussot, Director, Roche Holding, Former Chairman & CEO, Wyeth, Prix Galien Medical Technology, Startup, Digital Health and Incubators, Accelerators and Equity Committee Chairman. "This great list of nominees reflects the undeniable courage, dedication, and passion behind each researcher continually working to deliver answers to patients around the world. We applaud their efforts and look forward to celebrating our shared goal of improving the human condition".
Among the digital health solution nominees, digital therapeutic providers include Click Therapeutics and Flow.is, and diagnostic provider Canvas DX. The full list is below.
Reference: The Galien Foundation Announces 2023 Prix Galien USA Nominees for "Best Digital Health Solution," "Best Medical Technology," "Incubators, Accelerators and Equity," and "Best Startup". NEW YORK, July 27, 2023 /PRNewswire.
New machine-learning approach could speed precision drug development
The approach, detailed this week in the journal Nature, uses a platform called Molecular Surface Interaction Fingerprinting (MaSIF) to design custom proteins that bind to drug-bound target proteins.
AI-enabled CGM app shows promise for glycemic control, weight management
The broader implications of this study suggest that digital health platforms like January V2 have the potential to play a crucial role in the future of chronic disease management,” the authors write.